ZA9811127B - Stabilized teriparatide solutions. - Google Patents

Stabilized teriparatide solutions.

Info

Publication number
ZA9811127B
ZA9811127B ZA9811127A ZA9811127A ZA9811127B ZA 9811127 B ZA9811127 B ZA 9811127B ZA 9811127 A ZA9811127 A ZA 9811127A ZA 9811127 A ZA9811127 A ZA 9811127A ZA 9811127 B ZA9811127 B ZA 9811127B
Authority
ZA
South Africa
Prior art keywords
stabilized teriparatide
solutions
teriparatide solutions
stabilized
teriparatide
Prior art date
Application number
ZA9811127A
Other languages
English (en)
Inventor
Chin-Ming Chang
Henry A Havel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9811127(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA9811127B publication Critical patent/ZA9811127B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
ZA9811127A 1997-12-09 1998-12-04 Stabilized teriparatide solutions. ZA9811127B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
ZA9811127B true ZA9811127B (en) 2000-07-11

Family

ID=22086574

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811127A ZA9811127B (en) 1997-12-09 1998-12-04 Stabilized teriparatide solutions.

Country Status (32)

Country Link
EP (2) EP0920873B1 (ru)
JP (1) JP4405666B2 (ru)
KR (1) KR100482703B1 (ru)
CN (1) CN1198644C (ru)
AR (1) AR018526A1 (ru)
AT (1) ATE260113T1 (ru)
AU (1) AU759726B2 (ru)
BR (1) BR9813463A (ru)
CA (1) CA2314313C (ru)
CY (1) CY1114000T1 (ru)
CZ (1) CZ302401B6 (ru)
DE (1) DE69821872T2 (ru)
DK (2) DK0920873T3 (ru)
EA (1) EA004761B1 (ru)
EG (1) EG23675A (ru)
ES (2) ES2215268T3 (ru)
HK (1) HK1021798A1 (ru)
HU (1) HU230784B1 (ru)
ID (1) ID27741A (ru)
IL (1) IL136662A (ru)
MY (1) MY120063A (ru)
NO (1) NO327302B1 (ru)
NZ (1) NZ505222A (ru)
PE (1) PE20000001A1 (ru)
PL (1) PL194268B1 (ru)
PT (2) PT1417972E (ru)
SK (1) SK288203B6 (ru)
TR (1) TR200002134T2 (ru)
TW (1) TW570811B (ru)
UA (1) UA72884C2 (ru)
WO (1) WO1999029337A1 (ru)
ZA (1) ZA9811127B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
IL147731A0 (en) * 2000-05-19 2002-08-14 Bionebraska Inc Peptide pharmaceutical formulations
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
AU2002363412A1 (en) * 2001-11-05 2003-05-19 Eli Lilly And Company Method for improving stability of a bone-connecting implant
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CA2518903C (en) 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
ES2409351T3 (es) 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
EP2457580A1 (en) * 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
MX2009003569A (es) 2006-10-03 2009-08-25 Radius Health Inc Metodo de administracion de farmacos para la proteina anabolica osea.
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
ES2843649T3 (es) * 2009-09-09 2021-07-20 Asahi Kasei Pharma Corp Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
ES2917973T3 (es) 2011-06-14 2022-07-12 Neurelis Inc Administración de benzodiacepina
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
AU2016256470B2 (en) 2015-04-29 2020-10-15 Radius Pharmaceuticals, Inc. Methods of treating cancer
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
CN115025239A (zh) 2016-03-01 2022-09-09 阿森迪斯药物骨疾病股份有限公司 Pth前药
ES2943720T3 (es) 2016-09-29 2023-06-15 Ascendis Pharma Bone Diseases As Compuestos de PTH con bajas relaciones de pico a valle
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
WO2019059302A1 (ja) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP6637220B2 (ja) 2017-09-22 2020-01-29 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 Ｎ－ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
SG11202107722VA (en) * 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
AU2021208601A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
IT1255723B (it) † 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) † 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
TW570811B (en) 2004-01-11
EP1417972B1 (en) 2013-04-10
JP4405666B2 (ja) 2010-01-27
HUP0004447A3 (en) 2003-06-30
KR100482703B1 (ko) 2005-04-14
PE20000001A1 (es) 2000-01-17
IL136662A0 (en) 2001-06-14
HK1021798A1 (en) 2000-07-07
CZ20002115A3 (en) 2001-05-16
ES2215268T3 (es) 2004-10-01
ID27741A (id) 2001-04-26
SK15322000A3 (sk) 2001-05-10
EP0920873A2 (en) 1999-06-09
EP1417972A1 (en) 2004-05-12
BR9813463A (pt) 2000-10-10
NZ505222A (en) 2003-05-30
AU1717799A (en) 2005-05-16
PT1417972E (pt) 2013-05-24
KR20010032881A (ko) 2001-04-25
SK288203B6 (sk) 2014-07-02
AR018526A1 (es) 2001-11-28
CZ302401B6 (cs) 2011-05-04
EP1417972B2 (en) 2018-08-22
ATE260113T1 (de) 2004-03-15
DE69821872T2 (de) 2005-01-05
CA2314313C (en) 2005-02-08
PL340902A1 (en) 2001-03-12
CN1281370A (zh) 2001-01-24
EP0920873B1 (en) 2004-02-25
CY1114000T1 (el) 2016-07-27
CN1198644C (zh) 2005-04-27
JP2001525372A (ja) 2001-12-11
PT920873E (pt) 2004-06-30
PL194268B1 (pl) 2007-05-31
ES2405994T5 (es) 2019-01-30
EA004761B1 (ru) 2004-08-26
EP0920873A3 (en) 1999-08-04
WO1999029337A1 (en) 1999-06-17
DK1417972T4 (en) 2018-10-22
NO327302B1 (no) 2009-06-02
CA2314313A1 (en) 1999-06-17
NO20002945D0 (no) 2000-06-08
AU759726B2 (en) 2003-04-17
ES2405994T3 (es) 2013-06-04
TR200002134T2 (tr) 2000-11-21
DK0920873T3 (da) 2004-06-28
MY120063A (en) 2005-08-30
IL136662A (en) 2004-09-27
HUP0004447A2 (hu) 2001-04-28
EG23675A (en) 2007-04-15
EA200000629A1 (ru) 2000-12-25
UA72884C2 (ru) 2005-05-16
NO20002945L (no) 2000-07-07
DK1417972T3 (da) 2013-05-13
HU230784B1 (en) 2018-05-02
DE69821872D1 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
ZA9811127B (en) Stabilized teriparatide solutions.
ZA9811407B (en) Crystalline teriparatide.
ZA983864B (en) Communications system.
HK1017317A1 (en) Printer.
HK1016976A1 (en) Resorcinyl-triazine.
ZA981926B (en) Detergent--package combination.
ZA987055B (en) Substituted 4-benzoylpyrazoles.
DE59804842D1 (en) Aliphatische, emissionsarme, sinterfähige thermoplastische polyurethanformmassen
ZA987058B (en) Substituted 4-benzoylpyrazoles.
HK1017834A1 (en) Bodyshaper.
HK1021879A1 (en) Carrying case.
HK1022974A1 (en) Order entry system.
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA987B (en) Substituted 4-benzoylpyrazoles.
MXPA98005558A (es) Sistema de estabilizacion estructural.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
HK1017240A1 (en) Clip.
HK1028588A1 (en) Case.
ZA983795B (en) Substituted 4-benzoyl-pyrazoles.
ZA98263B (en) O-fucosyltransferase.
ZA983698B (en) Estrenes.
ZA976874B (en) Roofing.
ZA989435B (en) Novel aryloxy-alkyl-dialkylamines.
ZA983532B (en) Sensors.
ZA983706B (en) Pregnanes.